Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 51.90p 0 08:00:20
Bid Price Offer Price High Price Low Price Open Price
50.00p 53.80p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.02 -3.78 -2.30 68.7

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
16/1/201913:29Silence Therapeutics (the old SR Pharma)47,688
06/10/201608:04Gower Productions Presents ....."PREDICTA BID"52
29/5/201309:32Silence Therapeutics - news and views1,412
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-01-22 16:29:0050.207738.65AT
2019-01-22 16:29:0050.205527.61AT
2019-01-22 16:29:0050.205628.11AT
2019-01-22 16:29:0050.208542.67AT
2019-01-22 16:12:3350.20554278.11AT
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 51.90p.
Silence Ther. has a 4 week average price of 49.50p and a 12 week average price of 49.50p.
The 1 year high share price is 206p while the 1 year low share price is currently 49.50p.
There are currently 132,322,452 shares in issue and the average daily traded volume is 16,050 shares. The market capitalisation of Silence Ther. is £68,675,352.59.
callumross: Well, there is certainly plenty newsflow expected in the next 6 weeks to drive the share price up (or down!). To recap, Quark phase 3 results, High Court case against Alnylam commencing and application for phase 1 trial.
1gw: Interesting to compare the shares on loan position with the share price chart. According to Euroclear, SoL monthly average this year is as follows: 1.4m Jan (average shares on loan) 1.4m Feb 2.6m Mar 4.3m Apr 4.2m May 4.2m Jun 4.1m Jul 3.9m Aug 2.3m Sep So it looks like a significant increase in short positions in March and April (assuming the SoL correlates to short positions) may have helped to knock the shareprice off its 200p perch. hTtps://
tshirley12: Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
1gw: I missed the Nasdaq reference at first glance. Interesting. I get the impression this is a management team with more than half an eye focused on the share price and the potential to support the price with the carefully managed release of information.
1gw: Nice bit of profit-taking on the arwr stake. I wonder what that will do to the arwr share price today? And whether it's all part of the game to get some meaningful dialogue going with arwr?
rogen83: Arrowhead stake now worth £20m or 30p of SLNs share price Good work Ali
1gw: It has at least put the brakes on the share price. Who knows - if there's any truth to the suggestions that Alnylam might look to settle the patent dispute by taking over Silence then now might be a good time to strike. Certainly it seemed to me from the Alnylam call that Alnylam see the Fitusiran death as tragic but by no means an end to their hopes for the drug.
1gw: I can't help feeling there's an element of SLN investors looking at the ARWR price trajectory and thinking something's happening - and ARWR investors looking at the SLN price trajectory and thinking the same. Hopefully there's some substance behind both moves rather than mutually reinforcing illusions...
1gw: I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter.
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190123 08:58:54